Lipids Specialists Can Help Families With Heterozygous Familial Hypercholesterolemia Minimize The Risk Of Heart Disease

No Comments

Treatment options for heterozygous familial hypercholesterolemia usually involve a variety of treatments as well as vigilant changes in lifestyle, diet and exercise designed to minimize symptoms and delay the onset of coronary artery disease and other heart problems. Because only about one in five hundred … Read More



New HoFH drug, KYNAMRO, approved by the FDA

No Comments

On January 29th, 2013, Genzyme (a Sanofi company), and Isis Pharmaceuticals Inc. announced that after two years of patient clinical trials the US Food and Drug Administration has approved Kynamro ™ (generic name: mipomersen sodium) for the treatment of Homozygous Familial Hypercholesterolemia, the … Read More








FDA Approves New Treatment for HoFH

No Comments

On Dec 24th, 2012 Aegerion Pharmaceuticals, Inc. announced that the U.S. Food & Drug Administration (FDA) approved new treatment for Homozygous Familial Hypercholesterolemia (HoFH) called JUXTAPID™ (lomitapide). The capsules are intended as an adjunct to a low-fat diet and other cholesterol-lowering … Read More